Better Pharmaceutical: Submitting application for the listing of Enzalutamide Hydrochloride.

Betta Pharmaceuticals announced that the company has recently submitted an application for the marketing approval of Enzatinib Hydrochloride capsules to the Macau Drug Regulatory Authority. The drug, marketed as Beimina, is intended for the treatment of locally advanced or metastatic non-small cell lung cancer in patients with anaplastic lymphoma kinase-positive mutations. Enzatinib is a novel, highly potent, and selective next-generation ALK inhibitor developed jointly by the company and its subsidiary Xcovery. The drug has already obtained approval for marketing in China and the United States, and the application for marketing approval in Europe is currently underway. The company will continue to monitor the progress of the review process, and in the short term, this application will not have a significant impact on the company's business performance.